These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 15682409)

  • 1. Long-term remission from life-threatening hypercoagulable state associated with lupus anticoagulant (LA) following rituximab therapy.
    Ahn ER; Lander G; Bidot CJ; Jy W; Ahn YS
    Am J Hematol; 2005 Feb; 78(2):127-9. PubMed ID: 15682409
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term observation of patients with anti-neutrophil cytoplasmic antibody-associated vasculitis treated with rituximab.
    Stasi R; Stipa E; Del Poeta G; Amadori S; Newland AC; Provan D
    Rheumatology (Oxford); 2006 Nov; 45(11):1432-6. PubMed ID: 16632482
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rituximab chimeric anti-CD20 monoclonal antibody treatment for adult refractory idiopathic thrombocytopenic purpura.
    Braendstrup P; Bjerrum OW; Nielsen OJ; Jensen BA; Clausen NT; Hansen PB; Andersen I; Schmidt K; Andersen TM; Peterslund NA; Birgens HS; Plesner T; Pedersen BB; Hasselbalch HC
    Am J Hematol; 2005 Apr; 78(4):275-80. PubMed ID: 15795920
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Remission of proliferative lupus nephritis following B cell depletion therapy is preceded by down-regulation of the T cell costimulatory molecule CD40 ligand: an open-label trial.
    Sfikakis PP; Boletis JN; Lionaki S; Vigklis V; Fragiadaki KG; Iniotaki A; Moutsopoulos HM
    Arthritis Rheum; 2005 Feb; 52(2):501-13. PubMed ID: 15693003
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Complete remission of relapsed mixed cellularity Hodgkin's disease treated with rituximab].
    Al-Ali HK; Wittekind C; Niederwieser D
    Dtsch Med Wochenschr; 2007 Aug; 132(33):1688-91. PubMed ID: 17713864
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anti-CD20 monoclonal antibody (Rituximab) for life-threatening hemolytic-uremic syndrome.
    Yassa SK; Blessios G; Marinides G; Venuto RC
    Clin Transplant; 2005 Jun; 19(3):423-6. PubMed ID: 15877809
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High prevalence of hypercoagulable states in patients with recurrent thrombosis of mechanical heart valves.
    Gencbay M; Turan F; Degertekin M; Eksi N; Mutlu B; Unalp A
    J Heart Valve Dis; 1998 Nov; 7(6):601-9. PubMed ID: 9870192
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rituximab as successful therapy in a patient with refractory paroxysmal cold hemoglobinuria.
    Koppel A; Lim S; Osby M; Garratty G; Goldfinger D
    Transfusion; 2007 Oct; 47(10):1902-4. PubMed ID: 17880618
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Systemic eight-cycle anti-CD20 monoclonal antibody (rituximab) therapy in primary cutaneous B-cell lymphomas--an applicational observation.
    Gellrich S; Muche JM; Wilks A; Jasch KC; Voit C; Fischer T; Audring H; Sterry W
    Br J Dermatol; 2005 Jul; 153(1):167-73. PubMed ID: 16029344
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Splenic marginal zone lymphoma associated with antiphospholipid antibodies].
    Yokoi T; Mori S; Sugimoto H; Komiyama Y; Uemura Y; Tanijiri R; Nakai K; Matsumoto N; Zen K; Amakawa R; Kishimoto Y; Ieko M; Takahashi H; Fukuhara S
    Rinsho Ketsueki; 2004 Oct; 45(10):1095-9. PubMed ID: 15553043
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Consolidation treatment with rituximab induces complete and persistent remission of mixed type Evans syndrome.
    Rodella E; Pacquola E; Bianchini E; Ramazzina E; Paolini R
    Blood Coagul Fibrinolysis; 2008 Jun; 19(4):315-8. PubMed ID: 18469554
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term comparison of rituximab treatment for refractory systemic lupus erythematosus and vasculitis: Remission, relapse, and re-treatment.
    Smith KG; Jones RB; Burns SM; Jayne DR
    Arthritis Rheum; 2006 Sep; 54(9):2970-82. PubMed ID: 16947528
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Budd Chiari syndrome, visceral arterial occlusions, recurrent fetal loss and the "lupus anticoagulant" in systemic lupus erythematosus.
    Asherson RA; Thompson RP; MacLachlan N; Baguley E; Hicks P; Hughes GR
    J Rheumatol; 1989 Feb; 16(2):219-24. PubMed ID: 2746566
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rituximab therapy in adult patients with relapsed or refractory immune thrombocytopenic purpura: long-term follow-up results.
    Medeot M; Zaja F; Vianelli N; Battista M; Baccarani M; Patriarca F; Soldano F; Isola M; De Luca S; Fanin R
    Eur J Haematol; 2008 Sep; 81(3):165-9. PubMed ID: 18510702
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rituximab therapy for childhood-onset systemic lupus erythematosus.
    Willems M; Haddad E; Niaudet P; Koné-Paut I; Bensman A; Cochat P; Deschênes G; Fakhouri F; Leblanc T; Llanas B; Loirat C; Pillet P; Ranchin B; Salomon R; Ulinski T; Bader-Meunier B;
    J Pediatr; 2006 May; 148(5):623-627. PubMed ID: 16737873
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Activated protein C resistance and lupus anticoagulant activity induced by plasma and purified monospecific human IgG anti-beta2-glycoprotein-I antibodies.
    Viveros ME; Cabiedes J; Reyes E; Cabral AR
    Rev Invest Clin; 2005; 57(4):563-71. PubMed ID: 16315641
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Efficacy of rituximab in a case of refractory bullous pemphigoid].
    Reguiaï Z; Tchen T; Perceau G; Bernard P
    Ann Dermatol Venereol; 2009 May; 136(5):431-4. PubMed ID: 19442800
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Low rate of long-lasting remissions after successful treatment of immune thrombocytopenic purpura with rituximab.
    Schweizer C; Reu FJ; Ho AD; Hensel M
    Ann Hematol; 2007 Oct; 86(10):711-7. PubMed ID: 17622529
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-effectiveness of maintenance rituximab treatment after second line therapy in patients with follicular lymphoma in Sweden.
    Kasteng F; Erlanson M; Hagberg H; Kimby E; Relander T; Lundkvist J
    Acta Oncol; 2008; 47(6):1029-36. PubMed ID: 18607857
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rituximab for rescue and maintenance therapy in rapidly progressive life-threatening antineutrophil cytoplasmic autoantibody-associated systemic vasculitis.
    José RJ; Chrysochou C; Shurrab AE; New D; Wood GN
    Scand J Urol Nephrol; 2010 Dec; 44(6):459-62. PubMed ID: 20645677
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.